Supplemental Data (unaudited)

12 Months Ended

Dec. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Supplemental data (unaudited)

The following information is presented as supplemental data as required by the indentures governing the Company’s Senior Notes.

Condensed Consolidating Statements of Income



For the year ended December 31, 2018	Consolidated Total			Physician Groups			Unrestricted Subsidiaries		Company and Restricted Subsidiaries⁽¹⁾
Dialysis and related lab patient service revenues	$	10,709,981		$	—		$	—	$	10,709,981
Less: Provision for uncollectible accounts	(49,587		)	—			—		(49,587		)
Net dialysis and related lab patient service revenues	10,660,394			—			—		10,660,394
Other revenues	744,457			—			—		744,457
Total net revenues	11,404,851			—			—		11,404,851
Operating expenses and charges	9,879,027			—			—		9,879,027
Operating income	1,525,824			—			—		1,525,824
Debt expense	(487,435		)	—			—		(487,435		)
Other income, net	10,089			—			—		10,089
Income tax expense	258,400			—			—		258,400
Net income from continuing operations	790,078			—			—		790,078
Net (loss) income from discontinued operations, net of tax	(457,038		)	37,373			92		(494,503		)
Net income	333,040			37,373			92		295,575
Less: Net income attributable to noncontrolling interests	(173,646		)	(7,841		)	—		(165,805		)
Net income attributable to DaVita Inc.	$	159,394		$	29,532		$	92	$	129,770

Condensed Consolidating Statements of Comprehensive Income



For the year ended December 31, 2018	Consolidated Total			Physician Groups			Unrestricted Subsidiaries		Company and Restricted Subsidiaries⁽¹⁾
Net income	$	333,040		$	37,373		$	92	$	295,575
Other comprehensive loss	(39,791		)	—			—		(39,791		)
Total comprehensive income	293,249			37,373			92		255,784
Less: Comprehensive income attributable to noncontrolling interest	(173,646		)	(7,841		)	—		(165,805		)
Comprehensive income attributable to DaVita Inc.	$	119,603		$	29,532		$	92	$	89,979


(1)	After the elimination of the unrestricted subsidiaries and the physician groups

Condensed Consolidating Balance Sheets



As of December 31, 2018	Consolidated Total		Physician Groups		Unrestricted Subsidiaries		Company and Restricted Subsidiaries⁽¹⁾
Cash and cash equivalents	$	323,038	$	—	$	—	$	323,038
Restricted cash and equivalents	92,382		—		—		92,382
Accounts receivable, net	1,858,608		—		—		1,858,608
Other current assets	760,566		—		—		760,566
Other current assets held for sale	5,389,565		532,050		2,825		4,854,690
Total current assets	8,424,159		532,050		2,825		7,889,284
Property and equipment, net	3,393,669		—		—		3,393,669
Amortizable intangibles, net	118,846		—		—		118,846
Other long-term assets	331,618		—		—		331,618
Goodwill	6,841,960		—		—		6,841,960
Total assets	$	19,110,252	$	532,050	$	2,825	$	18,575,377
Current liabilities	$	3,647,402	$	—	$	—	$	3,647,402
Current liabilities held for sale	1,243,759		351,925		—		891,834
Total current liabilities	4,891,161		351,925		—		4,539,236
Payables to parent	—		25,456		2,825		(28,281		)
Long-term debt and other long-term liabilities	9,186,052		—		—		9,186,052
Noncontrolling interests subject to put provisions	1,124,641		—		—		1,124,641
Total DaVita Inc. shareholders' equity	3,703,442		154,669		—		3,548,773
Noncontrolling interests not subject to put provisions	204,956		—		—		204,956
Shareholders' equity	3,908,398		154,669		—		3,753,729
Total liabilities and shareholders' equity	$	19,110,252	$	532,050	$	2,825	$	18,575,377

Condensed Consolidating Statements of Cash Flow



For the year ended December 31, 2018	Consolidated Total			Physician Groups			Unrestricted Subsidiaries			Company and Restricted Subsidiaries⁽¹⁾
Cash flows from operating activities:
Net income	$	333,040		$	37,373		$	92		$	295,575
Changes in operating and intercompany assets and liabilities and non-cash items included in net income	1,438,600			81,722			(92		)	1,356,970
Net cash provided by operating activities	1,771,640			119,095			—			1,652,545
Cash flows from investing activities:
Additions of property and equipment	(987,138		)	(2,746		)	—			(984,392		)
Acquisitions and divestitures, net	(183,156		)	—			—			(183,156		)
Proceeds from asset sales	150,205			—			—			150,205
Investments and other items, net	14,446			(154		)	—			14,600
Net cash used in investing activities	(1,005,643		)	(2,900		)	—			(1,002,743		)
Cash flows from financing activities:
Long-term debt and related financing costs, net	694,777			—			—			694,777
Intercompany	—			25,296			—			(25,296		)
Other items	(1,320,131		)	—			—			(1,320,131		)
Net cash (used in) provided by financing activities	(625,354		)	25,296			—			(650,650		)
Effect of exchange rate changes on cash	(3,350		)	—			—			(3,350		)
Net increase (decrease) in cash, cash equivalents and restricted cash	137,293			141,491			—			(4,198		)
Less: Net increase in cash, cash equivalents and restricted cash from discontinued operations	240,793			141,491			—			99,302
Net decrease in cash, cash equivalents and restricted cash from continuing operations	(103,500		)	—			—			(103,500		)
Cash, cash equivalents and restricted cash of continuing operations at beginning of the year	518,920			—			—			518,920
Cash, cash equivalents and restricted cash of continuing operations at end of the year	$	415,420		$	—		$	—		$	415,420

(1)

After the elimination of the unrestricted subsidiaries and the physician groups